text:
PortCityDaily.com is your source for free news and information in the Wilmington area.
Negotiations are underway to transform the Water Street parking deck into a mixed-use development in downtown Wilmington after City Council OK'd an agreement with East-West Partners on Tuesday night.
City Council approved a preliminary agreement with Chapel Hill-based East-West Partners, with the final agreement expected within six months, according to Wilmington City Manager Sterling Cheatham.
In February, council selected East-West Partners to enter into negotiations with the city to replace the structure, which the city plans to demolish and replace with a mixed-use development with residential housing and public and private parking.
The city would sell air rights for development above the current structure, the cost of which will be determined by a city-approved appraiser, according to Malissa Talbert, spokeswoman for the city.
Related story: City council selects Chapel Hill firm for Water Street parking deck redevelopment
The total project cost is estimated at $68 million. The city was initially expected to pay $18.7 million, but Talbert said East-West Partners will provide a cost estimate for the city's proposed investments within 180 days.
East-West Partners' proposal includes 190 residential units, 225 private parking spaces and 280 public spaces, nearly 24,000 square feet of retail along Water Street and 6,300 square feet of retail along Bijou Park. The city would retain ownership of the parking deck and East-West would lease or purchase the private lots, Talbert said.
But at least one local group has taken issue with proposal, as well as the process.
Paul Lawler, a member of the Residents of Old Wilmington (ROW), said one of the group's concerns is what the project will cost for city taxpayers, citing an expectation of $20 million from the city.
"Another concern was the loss of appealing design features," Lawler said.
"Some other features are now unclear and might or might not have been changed. These points should be clarified. The East-West plans indicated that the project would consume some space on Water Street."
According to Lawler, appraisals of the property "offered some startling information about the price of land."
"Its value is tanking, according to the appraisal," Lawler said. "The site was purchased for $4.7 million in 2007 and 2012. It is currently assessed by the county tax office at $3,326,000. The appraisals made for this project valued it at $2.5 million. That low value does not suggest that now is a good time to build apartments there."
Cheatham said the redeveloped property would include parking for area businesses to grow, provide public space and pedestrian-friendly connectivity to Front Street and include privately owned residential and retail uses that would increase the tax base and "result in more people living downtown, which will stimulate further economic development."
Related stories:


text: "Deliver Me From Negative Self Talk: A Guide To Speaking Faith-filled Words" by Lynn R Davis 2012 | EPUB | 90 pages | ISBN: 1481178350 | English | 0.1 MB If your self talk is negative and you're constantly doubting and down-talking yourself, this book is for you. God wants us to see ourselves the way He sees us. He wants our words and thoughts to be a reflection of His love. This self talk book will teach you to change your self talk and replace negative thoughts with positive reflections of faith. Deliver Me From Negative Self-talk will help you: * Stop the negative self-talk that is holding you back from God's best for your life * Speak life-giving words of faith in challenging times that will change your circumstances * Be a positive influence for others who are struggling with negativity. * Experience blessings and victory over fear, bad habits, addictions, negative emotions, sickness, relationships self-esteem, weight-loss and so much more. Deliver Me From Negative Self-talk offers daily devotionals as positive self-talk guides using scripture references. You will learn the power of positive self talk through scriptural based phrases. Life and death is in the power of your tongue ". Get "Deliver Me From Negative Self-Talk" and start declaring life instead of speaking negatively (death) over yourself and the ones you love. More in my Blog > click here... Buy Premium From My Links To Get Resumable Support,Max Speed & Support Me Code: Download ( NitroFlare ) http://nitroflare.com/view/1C244E7FEA54F70/tb21j.D.M.F.N.S.T.A.G.T.S.F.W.rar Oboom https://www.xxxxxxxx/46KZQBCD/tb21j.D.M.F.N.S.T.A.G.T.S.F.W.rar

subset: commoncrawl


text:
News By Tag
Industry News
News By Location
Industry News
Sixth Annual Diagnostic Coverage and Reimbursement Conference Set for December 2014
Payer and ACO Organizations to Present Perspectives on ACO Metrics, Goals, and Building Partnerships
At this year's conference, speakers include experts from payer organizations, Accountable Care Organizations, diagnostic companies and laboratories, and legal institutions to provide insight into best strategies for adhering to the evolving payer landscape and integration of ACOs. A wide variety of topics will be addressed, such as FDA regulations for lab developed testing, pricing strategies in light of payment reform, and MoPath codes for next-generation sequencing. Among the more than two dozen speakers set to present sessions and panels this year are Michael Kolodziej of Aetna, Charles Stemple of Humana, and Neeraj Chopra of Siemens Healthcare.
This year's conference also offers panel discussions that provide direct perspectives on some of the most timely issues within the diagnostic industry. An ACO roundtable, led by Joseph Rubino of BG Medicine, Robert Remstein of Capital Health System Hopewell Medical Center, and Sree Chaguturu of Partners Healthcare, will provide an in-depth and interactive look at the goals of ACOs as it relates to diagnostic tests, the impact on markets, best practices for accessing ACOs and building partnerships, and standards that ACOs use to make decisions. Attendees will also hear from Rina Wolf and Kyle Fetter of Xifin, and Brian Carey of Foley Hoag regarding the latest updates on the Protecting Access to Medicare Act of 2014, as it relates to overall reporting implementation, execution, and long-term financial impact.
For more information or to register for the 6th Annual Diagnostic Coverage and Reimbursement Conference, please visit www.q1productions.com/
About the Organizer
Q1 Productions designs and develops webinars, training courses, conference programs and forums aimed at specifically targeted audiences throughout highly regulated industries in order to provide strategic learning and timely program content. Through a highly structured production process focused on research calls with end-users and key stakeholders in the industry, our team is able to understand the immediate business concerns of today's leading executives. Whether focusing on new or pending legislative and health policy issues or enhanced technologies or processes that will drive efficiency, our programs provide solutions to the urgent educational and information needs of our attendees.
Erica Abdnour
Account Email Address Account Phone Number Disclaimer Report Abuse


text:
Glo hair & beauty Garristown – Full body He Shi Tan on special this week €15
Full body He Shi Tan on special this week €15
01 8355051
01 8355051
We do not guarantee the accuracy or timeliness of information available from our website. Every piece of information is valid only during the specified timeframe. In addition, the interpretation, modification, and usage rights for the message belong to the seller (or supplier) of the product (or service). Please see the Terms of Use.
Forgot password? Get a new password.


text:
NMRA Bowling Green Finals 2011 Same Day Coverage
It's that time of the year again for the always popular NMRA finals in Bowling Green, Kentucky. Virtually any class that is being led by 1000 points or less is still up for grabs. Also, Saturday will be the make up final eliminations for the NMRA Columbus rain out. Keep it tuned to Stang TV all weekend for the updates and videos from Bowling Green.
Special thanks to our event coverage sponsor SCT Performance, check their fine line of flash tuners out at www.sctflash.com.
Sunday Morning Pit Notes
Eliminations Notes
Final Round Updates
<< Previous Page 1 2 3 4 5 Next Page >>


text:
|Publication number
|Publication type
|Application number
|Publication date
|Jan 17, 2012
|Filing date
|Apr 6, 2010
|Priority date
|Jul 29, 1999
|Fee status
|Also published as
|Publication number
|John J. Donnelly, Kimberly S. Denis-Mize, Gary S. Ott
|Original Assignee
|Novartis Vaccines And Diagnostics, Inc.
|Export Citation
|BiBTeX, EndNote, RefMan
|Patent Citations (22), Non-Patent Citations (27), Referenced by (2), Classifications (14), Legal Events (2)
|External Links: USPTO, USPTO Assignment, Espacenet
This application is a divisional of U.S. application Ser. No. 09/715,902, filed Nov. 17, 1999, now U.S. Pat. No. 7,713,739 entitled MICROPARTICLE-BASED TRANSFECTION AND ACTIVATION OF DENDRITIC CELLS, which is a non-provisional of Provisional Application Ser. No. 60/166,514 filed Nov. 19, 1999, now expired, which are incorporated herein by reference in their entireties. This application is also related to Patent Application Ser. No. 60/146,391, filed Jul. 29, 1999, which is incorporated herein by reference in its entirety.
The present invention relates to compositions and methods of providing dendritic cells for immunotherapy in connection with, for example, viruses or tumors. In particular, the invention relates to methods for generating antigen presenting dendritic cells by transfection, allowing for, e.g., the activation and expansion of large numbers of viral- or tumor-antigen-specific T cells for use in adoptive cellular immunotherapy against viruses and tumors.
The generation of an immune response involves the sensitization of helper (CD4+) (TH) and cytotoxic (CD8+) (CTL) T cell subsets through their interaction with antigen presenting cells. Antigen presenting cells express major histocompatibility (MHC)-class I or class II molecules associated with antigenic fragments (i.e., specific amino acid sequences derived from an antigen which bind to MHC I and MHC II for presentation on the cell surface). The MHC in humans is also referred to as the HLA (human leukocyte antigen) complex. The sensitized CD4+ T cells produce lymphokines that participate in the activation of B cells as well as various T cell subsets. The sensitized CD8+ T cells increase in numbers in response to lymphokines and act to destroy cells that express the specific antigenic fragments associated with matching MHC-encoded class I molecules. In the course of a tumor or viral infection, cytotoxic T cells eradicate cells expressing tumor or virus associated antigens.
Dendritic cells (DCs) are thought to be the most potent antigen presenting cells of the immune system (reviewed in Steinman, R. M. 1991. The dendritic cells system and its role in immunogenicity. Ann. Rev. Immunol. 9:271; Banchereau, J. B. and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245). Given their broad spectrum of roles in initiating the immune response by internalizing and processing antigens, migrating to lymphoid organs, secreting cytokines, and expressing co-stimulatory molecules required for lymphocyte signaling, it is no surprise that dendritic cells are logical targets for clinical use (Banchereau, J. B. and R. M. Steinman. 1998. Dendritic cells and the control of immunity. Nature. 392:245). By targeting antigens into dendritic cells in vivo or exposing dendritic cells to antigen ex vivo, it may be possible to enhance the immunogenicity of vaccines by eliciting helper and cytotoxic T cells, antibodies, and IL-12 for prophylactic applications, or induce T cell mediated anti-tumor responses for cancer immunotherapy. Akbari, et al. have suggested that transfection and activation of dendritic cells are key events for immunity following DNA vaccination by scarification of the ear skin in mouse models (O. Akbari, N. P., S. Garcia, R. Tascon, D. Lowrie, and B. Stockinger. 1999. DNA vaccination: transfection and activation of dendritic cells as key events for immunity. J. Exp. Med. 189:169). Anti-tumor CTL activity and protection against lethal tumor challenge in mouse models have been demonstrated using cytokine-driven bone-marrow-derived dendritic cells (BMDCs) pulsed with tumor-associated peptides (J. I. Mayordomo, T. Z., W. J. Storkus. 1995. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nature Med. 1:1297), and whole tumor lysates (R. C. Fields, K. S., and J. J. Mule'. 1998. Murine dendritic cells pulsed with whole tumor lysates mediate potent antitumor immune responses in vitro and in vivo. Proc. Natl. Acad. Sci. USA 95:9482) transferred by the subcutaneous route.
In vitro generation of dendritic cells has been optimized sufficiently so that genetic immunotherapy based on passive transfer of dendritic cells has become an attractive target for development (N. Romani, S. G., D. Brang. 1994. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180:83). However, in vitro transfection efficiency of dendritic cells by non-viral methods has been extremely poor (J. F. Arthur, L. H. B., M. D. Roth, L. A. Bui, S. M. Kiertscher, R. Lau, S. Dubinett, J. Glaspy, W. H. McBride, and J. S. Economou. 1997. A comparison of gene transfer methods in human dendritic cells. Cancer Gene Ther. 4:17) and has limited progress toward effective dendritic-cell-based immunotherapy. While progress has been made by the use of electroporation, the efficiency of transfection is extremely low and results in substantial loss of cell viability (V. F. I. Van Tendeloo, H.-W. S., F. Lardon, GLEE Vanham, G. Nijs, M. Lenjou, L. Hendriks, C. Van Broeckhoven, A. Moulijn, I. Rodrigus, P. Verdonk, D. R. Van Bockstaele, and Z. N. Berneman. 1988. Nonviral transfection of distinct types of human dendritic cells: high efficiency gene transfer by electroporation into hematopoietic progenitor- but not monocyte-derived dendritic cells. Gene Ther. 5:700). To date, no purely chemical method has been shown to be effective.
Particulate carriers have been used in order to achieve controlled, parenteral delivery of therapeutic compounds. Such carriers are designed to maintain the active agent in the delivery system for an extended period of time. Examples of particulate carriers include those derived from polymethyl methacrylate polymers, as well as microparticles derived from poly(lactides) (see, e.g., U.S. Pat. No. 3,773,919), poly(lactide-co-glycolides), known as PLG (see, e.g., U.S. Pat. No. 4,767,628) and polyethylene glycol, known as PEG (see, e.g., U.S. Pat. No. 5,648,095). Polymethyl methacrylate polymers are nondegradable while PLG particles biodegrade by random nonenzymatic hydrolysis of ester bonds to lactic and glycolic acids, which are excreted along normal metabolic pathways.
For example, U.S. Pat. No. 5,648,095 describes the use of microspheres with encapsulated pharmaceuticals as drug delivery systems for nasal, oral, pulmonary and oral delivery. Slow-release formulations containing various polypeptide growth factors have also been described. See, e.g., International Publication No. WO 94/12158, U.S. Pat. No. 5,134,122 and International Publication No. WO 96/37216.
Particulate carriers have also been used with adsorbed or entrapped antigens in attempts to elicit adequate immune responses. Such carriers present multiple copies of a selected antigen to the immune system and promote trapping and retention of antigens in local lymph nodes. The particles can be phagocytosed by macrophages and can enhance antigen presentation through cytokine release. For example, commonly owned, co-pending application Ser. No. 09/015,652, filed Jan. 29, 1998, describes the use of antigen-adsorbed and antigen-encapsulated microparticles to stimulate cell-mediated immunological responses, as well as methods of making the microparticles.
In commonly owned provisional Patent Application 60/036,316, for example, a method of forming microparticles is disclosed which comprises combining a polymer with an organic solvent, then adding an emulsion stabilizer, such as polyvinyl alcohol (PVA), then evaporating the organic solvent, thereby forming microparticles. The surface of the microparticles comprises the polymer and the stabilizer. Polynucleotides such as DNA, polypeptides, and antigens may then be adsorbed on those surfaces. See also PCT US99/17308.
Commonly owned Provisional Application No. 60/146,391 discloses a method of forming microparticles with adsorbent surfaces that are capable of adsorbing a variety of macromolecules including polynucleotides. In one embodiment, the microparticles are comprised of both a polymer and a detergent. The microparticles are derived from a polymer, such as a poly(α-hydroxy acid), preferably, a poly(D,L-lactide-co-glycolide), a polyhydroxy butyric acid, a polycaprolactone, a polyorthoester, a polyanhydride, a polycyanoacrylate, and the like, and are formed with detergents, such as cationic, anionic, or nonionic detergents, which detergents may be used in combination. Cationic detergents disclosed are cetrimide (CTAB), benzalkonium chloride, DDA (dimethyl dioctodecyl ammonium bromide), DOTAP, and the like. It is noted that these microparticles yield improved adsorption of viral antigens, and provide for superior immune responses, as compared to microparticles formed by a process using only PVA.
Dendritic cells can capture antigen at peripheral sites via macropinocytosis using membrane ruffling, or may also internalize antigen by receptor-mediated processes involving FcγIII, the mannose receptor, or the C-type lectin DEC-205 (reviewed in Lanzavecchia, A. 1996. Mechanisms of antigen uptake for presentation. Curr. Op. Immunol. 8:348). Thus, dendritic cells may be targeted by the capture of larger (>250 nm) particulate antigens by phagocytosis. Biodegradable polymer microspheres such as poly-lactide-co-glycolide (PLG) are readily internalized by phagocytic cells up to a diameter of 5 μm (Ikada, Y. T. et al. 1990. Phagocytosis of polymer microspheres by macrophages. Adv. Polymer. Sci. 94:107) and have been utilized as carriers for drug delivery systems.
Recently, Newman, et al. reported cytoplasmic delivery of Texas red labeled dextran encapsulated in PLGA microspheres following phagocytosis in mouse peritoneal macrophages (K. D. Newman, G. K., J. Miller, V. Chlumecky, J. Samuel. 1999. Cytoplasmic delivery of a fluorescent probe by poly(D,L lactic-co-glycolic acid) microspheres. In 1999 AAPS Annual Meeting Abstracts Online, vol. 1).
The application of synthetic biopolymers for nucleic acid delivery has proven advantageous by protecting DNA against nuclease degradation and increasing cellular uptake (C. Chavany, T. S.-B., T. Le Doan, F. Puisieux, P. Couvreur, and C. Helene. 1994. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11:1370).
Evidence for direct transfection of non professional antigen presenting cells mediated by PLG was recently reported by Ciftci and Su who found PLG microparticles containing a DNA:polycation complex provided controlled release of DNA and surfactant-enhanced uptake and gene expression in 293 and MCF-7 cells (K. Ciftci, J. S. 1999. DNA-PLGA microparticles: a promising delivery system for cancer gene therapy. In 1999 AAPS Annual Meeting Abstracts Online, vol. 1).
While polyalkylcyanoacrylate nanoparticles have been used to bind CTAB-oligonucleotide complexes to deliver antisense oligonucleotides to macrophage cell lines in vitro (C. Chavany, T. S.-B., T. Le Doan, F. Puisieux, P. Couvreur, and C. Helene. 1994. Adsorption of oligonucleotides onto polyisohexylcyanoacrylate nanoparticles protects them against nucleases and increases their cellular uptake. Pharm. Res. 11:1370; E. Fattal, C. V., I. Aynie, Y. Nakada, G. Lambert, C. Malvy, and P. Couvreur. 1998. Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides. J. Controlled Release 53:137), these vehicles have not been shown to transfect dendritic cells with plasmids carrying recombinant genes.
Hence, there is a need in the art for an effective non-viral technique for the transfection of dendritic cells. While microparticle technology has been heretofore used for introduction of polynucleotides into cells, applicants are aware of no such technology having been used for the transfection of dendritic cells, which are notoriously resistant to transfection.
The present invention provides an effective method for the transfection of dendritic cells by non-viral methods. The present invention provides this benefit by incubating dendritic cells and a specified transfection agent. The transfection agent comprises polynucleotide and microparticles, with the microparticles being comprised of a biodegradable polymer and a cationic detergent. The dendritic cells and transfection agent are incubated for a time sufficient to transfect the dendritic cells with the polynucleotide.
For the transfecting agent, the cationic detergent preferably comprises CTAB or cetrimide, while the polymer preferable is a poly(α-hydroxy acid), for example, a poly(lactide), a copolymer of D,L-lactide and caprolactone, or a copolymer of D,L-lactide and glycolide or glycolic acid, such as poly(D,L-lactide-co-glycolide). In a further preferred embodiment, the polynucleotide is provided in the form of a plasmid. In still further preferred embodiments, the polynucleotide encodes an antigen associated with a virus, such as HIV, meningitis A, meningitis B or meningitis C, or a tumor.
The dendritic cells can originate from any available source, for example, the bone marrow or blood of a vertebrate subject, preferably a human subject. Dendritic cells can be cultured, for example, for about 5 to about 10 days prior to transfection, in the presence of appropriate growth factors, for example, GM-CSF.
The dendritic cells and transfecting agent are preferably incubated for about 24 hours under appropriate conditions.
In some embodiments of the present invention, an effective amount of the transfected dendritic cells of the present invention are administered to a vertebrate subject in need thereof. In other embodiments, T cells are first activated by the dendritic cells of the present invention and then administered to a vertebrate subject in need thereof. The dendritic cells and/or T cells may originate, for example, from the vertebrate subject or a healthy vertebrate subject MHC-matched to the vertebrate subject. The dendritic cells and or T cells may be administered parenterally to the vertebrate subject.
One advantage of the present invention is that polynucleotides can be efficiently internalized by dendritic cells.
Another advantage of the present invention is that gene expression can be effected within dendritic cells.
Yet another advantage of the present invention is that antigen can be processed and presented in connection with MHC molecules on the surface of dendritic cells.
Another advantage of the present invention is that polynucleotides can be rapidly internalized and expressed, with antigen presentation.
Still another advantage of the present invention is that the methods of the invention can be used, for example, in genetic immunotherapy or vaccination with relative safely. For instance, both cationic detergents, such as CTAB, and biodegradable polymers, such as PLG, have been utilized in biomedical applications. Moreover, the obvious safety concerns with the use of live viral vectors can be avoided (reviewed in Rock, S. R. et al. 1998. Fully mobilizing host defense: building better vaccines. Nature Biotech. 16:1025).
These and other embodiments and advantages will become readily apparent to those skilled in the art upon review of this specification and the claims set forth below.
The practice of the present invention will employ, unless otherwise indicated, conventional methods of chemistry, polymer chemistry, biochemistry, molecular biology, immunology and pharmacology, within the skill of the art. Such techniques are explained fully in the literature. See, e.g., Remington's Pharmaceutical Sciences, 18th Edition (Easton, Pa.: Mack Publishing Company, 1990); Methods In Enzymology (S. Colowick and N. Kaplan, eds., Academic Press, Inc.); Handbook of Experimental Immunology, Vols. I-IV (D. M. Weir and C. C. Blackwell, eds., 1986, Blackwell Scientific Publications); Sambrook, et al., Molecular Cloning: A Laboratory Manual (2nd Edition, 1989); Handbook of Surface and Colloidal Chemistry (Birdi, K. S., ed, CRC Press, 1997) and Seymour/Carraher's Polymer Chemistry (4th edition, Marcel Dekker Inc., 1996).
All publications, patents and patent applications cited herein, whether supra or infra, are hereby incorporated by reference in their entirety.
In describing the present invention, the following terms will be employed, and are intended to be defined as indicated below.
The term "dendritic cells" is used herein to refer to antigen presenting cells characterized by their peculiar dendritic morphology and multiple thin-membrane projections, and by their high density of class II MHC molecules. Dendritic cells include Langerhans cells of the skin, "veiled cells" of afferent lymphatics, follicular dendritic cells, dendritic cells of the spleen, and interdigitating cells of lymphoid organs. Dendritic cells can be obtained from the skin, spleen, bone marrow, lymph nodes, other lymphoid organs, and peripheral blood cord blood. Preferably, dendritic cells are obtained from blood or bone marrow for use in the invention.
The term "microparticle" as used herein, refers to a particle of about 100 nm to about 150 μm in diameter, more preferably about 200 nm to about 30 μm in diameter, and most preferably about 500 nm to about 10 μm in diameter. Microparticle size is readily determined by techniques well known in the art, such as photon correlation spectroscopy, laser diffractometry and/or scanning electron microscopy.
Microparticles for use herein are preferably formed from materials that are preferable sterilizable, non-toxic and biodegradable. Such materials include, without limitation, poly(α-hydroxy acid), polyhydroxybutyric acid, polycaprolactone, polyorthoester, polyanhydride, PACA, and polycyanoacrylate. Preferably, microparticles for use with the present invention are derived from a poly(α-hydroxy acid), in particular, from a poly(lactide) ("PLA") or a copolymer of D,L-lactide and glycolide or glycolic acid, such as a poly(D,L-lactide-co-glycolide) ("PLG" or "PLGA"), or a copolymer of D,L-lactide and caprolactone. The microparticles may be derived from any of various polymeric starting materials which have a variety of molecular weights and, for example, in the case of the copolymers such as PLG, a variety of co-monomer (lactide:glycolide) ratios.
The term "cationic detergent" as used herein includes cationic surfactants and emulsion stabilizers. Cationic detergents include, but are not limited to, cetrimide, CTAB, benzalkonium chloride, DDA (dimethyl dioctodecyl ammonium bromide), Dioleoyl-3-Trimethylammonium-Propane (DOTAP), and the like.
A "polynucleotide" is a nucleic acid polymer. Polynucleotides according to the present invention are preferably of the minimum transfection unit length, which is on the order of about 1 kb. Furthermore, a "polynucleotide" can include both double- and single-stranded sequences, and can include naturally derived and synthetic DNA sequences. The term also includes sequences that include any of the known base analogs of DNA and RNA, and includes modifications, such as deletions, additions and substitutions (generally conservative in nature) to native sequences.
The terms "polypeptide" and "protein" refer to a polymer of amino acid residues and are not limited to a minimum length of the product. Thus, peptides, oligopeptides, dimers, multimers, and the like, are included within the definition. Both full-length proteins and fragments thereof are encompassed by the definition. The terms also include modifications, such as deletions, additions and substitutions (generally conservative in nature), to native sequence.
By "antigen" is meant a molecule that contains one or more epitopes capable of stimulating an immunological response when the antigen is presented on a dendritic cell surface in accordance with the present invention. Normally, an epitope will include between about 3-15, generally about 5-15, amino acids. Epitopes of a given protein can be identified using any number of epitope mapping techniques, well known in the art. See, e.g., Epitope Mapping Protocols in Methods in Molecular Biology, Vol. 66 (Glenn E. Morris, Ed., 1996) Humana Press, Totowa, N. J. For example, linear epitopes may be determined by, e.g., concurrently synthesizing large numbers of peptides on solid supports, the peptides corresponding to portions of the protein molecule, and reacting the peptides with antibodies while the peptides are still attached to the supports. Such techniques are known in the art and described in, e.g., U.S. Pat. No. 4,708,871; Geysen et al. (1984) Proc. Natl. Acad. Sci. USA 81:3998-4002; Geysen et al. (1986) Molec. Immunol. 23:709-715, all incorporated herein by reference in their entireties. Similarly, conformational epitopes are readily identified by determining spatial conformation of amino acids such as by, e.g., x-ray crystallography and 2-dimensional nuclear magnetic resonance. See, e.g., Epitope Mapping Protocols, supra.
For purposes of the present invention, antigens can be derived from any of several known viruses, bacteria, parasites and fungi, as well as any of the various tumors. Furthermore, for purposes of the present invention, an "antigen" refers to a protein, which includes modifications, such as deletions, additions and substitutions (generally conservative in nature), to the native sequence, so long as the ability to elicit an immunological response is maintained. These modifications may be deliberate, as through site-directed mutagenesis, or may be accidental, such as through mutations of hosts that produce the antigens.
An "immunological response" or "immune response" is the development in a subject of a humoral and/or a cellular immune response to molecules present in the composition of interest. For purposes of the present invention, a "humoral immune response" refers to an immune response mediated by antibody molecules, while a "cellular immune response" is one mediated by T-lymphocytes and/or other white blood cells. Thus, an immunological response as used herein may be one which stimulates the production of cytotoxic T cells, and/or the production or activation of helper T-cells. Such responses can be determined using standard immunoassays and neutralization assays, well known in the art.
Vaccines and immunogenic compositions are both contemplated in connection with the present invention.
By "vertebrate subject" is meant any member of the subphylum cordata, including, without limitation, mammals such as cattle, sheep, pigs, goats, horses, and humans; domestic animals such as dogs and cats; and birds, including domestic, wild and game birds such as cocks and hens including chickens, turkeys and other gallinaceous birds. The term does not denote a particular age. Thus, both adult and newborn animals are intended to be covered.
By "pharmaceutically acceptable" or "pharmacologically acceptable" is meant a material which is not biologically or otherwise undesirable, i.e., the material may be administered to an individual without causing any undesirable biological effects or interacting in a deleterious manner with any of the components of the composition in which it is contained.
In the present invention, a polynucleotide comprising an antigen of interest is adsorbed upon microparticles formed from a polymer and a cationic detergent.
The adsorption of polynucleotides to the surface of the adsorbent microparticles occurs via any bonding-interaction mechanism, including, but not limited to, ionic bonding, hydrogen bonding, covalent bonding, Van der Waals bonding, and bonding through hydrophilic/hydrophobic interactions. Those of ordinary skill in the art may readily select cationic detergents appropriate for the invention. As noted above, known cationic detergents include, but are not limited to, cetyl trimethyl ammonium bromide (CTAB), cetrimide (a mixture consisting chiefly of tetradecyltrimethylammonium bromide, together with smaller amounts of dodecyltrimethylammonium bromide and CTAB), benzalkonium chloride, DDA (dimethyl dioctodecyl ammonium bromide), DOTAP, and the like. CTAB is particularly preferred. Microparticles manufactured with cationic detergents, such as CTAB, e.g., CTAB-PLG microparticles, readily adsorb negatively charged polynucleotides.
Biodegradable polymers for manufacturing microparticles for use with the present invention are readily commercially available from, e.g., Boehringer Ingelheim, Germany and Birmingham Polymers, Inc., Birmingham, Ala. For example, useful polymers for forming the microparticles herein include those derived from polyhydroxybutyric acid; polycaprolactone; polyorthoester; polyanhydride; as well as a poly(α-hydroxy acid), such as poly(L-lactide), poly(D,L-lactide) (both known as APLA" herein), poly(hydroxybutyrate), copolymers of D,L-lactide and glycolide, such as poly(D,L-lactide-co-glycolide) (designated as "PLG" or "PLGA" herein) or a copolymer of D,L-lactide and caprolactone. Particularly preferred polymers for use herein are PLA and PLG polymers. These polymers are available in a variety of molecular weights, and the appropriate molecular weight for a given use is readily determined by one of skill in the art. Thus, e.g., for PLA, a suitable molecular weight will be on the order of about 2000 to 5000. For PLG, suitable molecular weights will generally range from about 10,000 to about 200,000, preferably about 15,000 to about 150,000, and most preferably about 50,000 to about 100,000.
If a copolymer such as PLG is used to form the microparticles, a variety of lactide:glycolide ratios will find use herein. PLG copolymers with varying lactide:glycolide ratios and molecular weights are readily available commercially from a number of sources including from Boehringer Ingelheim, Germany and Birmingham Polymers, Inc., Birmingham, Ala. These polymers can also be synthesized by simple polycondensation of the lactic acid component using techniques well known in the art, such as described in Tabata et al., J. Biomed. Mater. Res. (1988) 22:837-858.
The polynucleotide/microparticles are prepared using any of several methods well known in the art. For example, double emulsion/solvent evaporation techniques, such as those described in U.S. Pat. No. 3,523,907 and Ogawa et al., Chem. Pharm. Bull. (1988) 36:1095-1103, can be used herein to make the microparticles.
A water-in-oil-in-water (w/o/w) solvent evaporation system can be used to form the microparticles, as described by O′Hagan et al., Vaccine (1993) 11:965-969 and Jeffery et al., Pharm. Res. (1993) 10:362. In this technique, the particular polymer is combined with an organic solvent, such as ethyl acetate, dimethylchloride (also called methylene chloride and dichloromethane), acetonitrile, acetone, chloroform, and the like. The polymer will be provided in about a 1-30%, preferably about a 2-15%, more preferably about a 3-10% and most preferably, about a 4% solution, in organic solvent. The polymer solution is emulsified using, e.g., a homogenizer. The emulsion is then optionally combined with a larger volume of an aqueous solution of an emulsion stabilizer such as polyvinyl alcohol (PVA), polyvinyl pyrrolidone, and a detergent, specifically a cationic detergent. The emulsion may be combined with more than one emulsion stabilizer and/or detergent, e.g., a combination of PVA and a cationic detergent. Certain polynucleotides may adsorb more readily to microparticles having a combination of stabilizers and/or detergents. Where an emulsion stabilizer is used, it is typically provided in about a 2-15% solution, more typically about a 4-10% solution. Generally, a weight-to-weight detergent to polymer ratio in the range of from about 0.00001:1 to about 0.1:1 will be used, more preferably from about 0.0001:1 to about 0.01:1, more preferably from about 0.001:1 to about 0.01:1, and even more preferably from about 0.005:1 to about 0.01:1. The mixture is then homogenized to produce a stable w/o/w double emulsion. Organic solvents are then evaporated.
The formulation parameters can be manipulated to allow the preparation of small microparticles on the order of 0.05 μm (50 nm) to larger microparticles 50 μm or even larger. See, e.g., Jeffery et al., Pharm. Res. (1993) 10:362-368; McGee et al., J. Microencap. (1996). For example, reduced agitation results in larger microparticles, as does an increase in internal phase volume. Small particles are produced by low aqueous phase volumes with high concentrations of emulsion stabilizers.
Microparticles can also be formed using spray-drying and coacervation as described in, e.g., Thomasin et al., J. Controlled Release (1996) 41:131; U.S. Pat. No. 2,800,457; Masters, K. (1976) Spray Drying 2nd Ed. Wiley, New York; air-suspension coating techniques, such as pan coating and Wurster coating, as described by Hall et al., (1980) The "Wurster Process" in Controlled Release Technologies: Methods, Theory, and Applications (A. F. Kydonieus, ed.), Vol. 2, pp. 133-154 CRC Press, Boca Raton, Fla. and Deasy, P. B., Crit. Rev. Ther. Drug Carrier Syst. (1988) S(2):99-139; and ionic gelation as described by, e.g., Lim et al., Science (1980) 210:908-910.
Particle size can be determined by, e.g., laser light scattering, using for example, a spectrometer incorporating a helium-neon laser. Generally, particle size is determined at room temperature and involves multiple analyses of the sample in question (e.g., 5-10 times) to yield an average value for the particle diameter. Particle size is also readily determined using scanning electron microscopy (SEM).
Following preparation, microparticles can be stored as is or freeze-dried for future use.
Dendritic cells are obtained from any tissue where they reside including non-lymphoid tissues such as the epidermis of the skin (Langerhans cells) and lymphoid tissues such as the spleen, bone marrow, lymph nodes and thymus as well as the circulatory system including blood (blood dendritic cells), for example peripheral blood and cord blood, and lymph (veiled cells).
For example, explants of mouse (Larsen et al., J. Exp. Med. 172:1483-1493 (1990)) or human skin (Richters et al., J. Invest. Dermatol. (1994)) placed in organ culture permit selective migration of dendritic cells into the medium surrounding the explant.
Recent studies have described methods for the isolation and expansion of human dendritic cells, including, from human peripheral blood. (Macatonia et al., 1991, Immunol. 74: 399-406; O′Doherty et al., 1993, J. Exp. Med. 178: 1067-1078 (isolation); and Markowicz et al., 1990, J. Clin. Invest. 85: 955-961; Romani et al., 1994, J. Exp. Med. 180: 83-93; Sallusto et al., 1994, J. Exp. Med. 179: 1109-1118; Berhard et al., 1995, J. Exp. Med. 55: 1099-1104 (expansion)).
Van Tendeloo et al., 1998, Gene Ther. 5: 700-707, discloses techniques for deriving dendritic cells (including Langerhans' cells) from CD34+ progenitor cells obtained from bone marrow and cord blood and from mononuclear cells from peripheral blood.
Dendritic cells may also be treated to induce maturation or activation, e.g., by culturing, preferably in the presence of a specific growth or stimulatory factor or factors. In the examples below, dendritic cells are modified by culturing with GM-CSF.
Additional techniques relating to the preparation of dendritic cells can be found, for example, in U.S. Pat. Nos. 5,788,963, 5,962,318, and 5,851,756, the disclosures of which are herein incorporated by reference.
According to a preferred embodiment of the invention, dendritic cells are obtained from a patient to be treated. The dendritic cells are used to activate T cells of the patient, either in vitro or in vivo, for immunotherapy
According to an alternate embodiment, dendritic cells are obtained from a healthy individual. The relevant HLA antigens (both class I and II, e.g., HLA-A, B, C and DR), for example, on the individual's peripheral blood mononuclear cells (PBMC's), are identified and dendritic cells that match the patient, in terms of HLA antigens, are isolated and expanded as described above. For example, in certain instances, a late stage cancer patient who has been treated with radiation and/or chemotherapy agents is not able to provide sufficient or efficient dendritic cells. Thus, dendritic cells from healthy HLA-matched individuals, such as siblings, can be obtained and expanded using any of the methods described above.
Selected antigens that may be expressed include one or more selected antigens of a vertebrate infectious agent or cancer and can correspond to either structural or non-structural proteins. The invention herein described can provide for association of such antigens with MHC molecules at the surface of dendritic cells such that an immune response to the antigen of interest can be mounted.
For example, the present invention is useful for stimulating an immune response against a wide variety of antigens from the herpes virus family, including proteins derived from herpes simplex virus (HSV) types 1 and 2, such as HSV-1 and HSV-2 glycoproteins gB, gD and gH; antigens derived from varicella zoster virus (VZV), Epstein-Barr virus (EBV) and cytomegalovirus (CMV) including CMV gB and gH; and antigens derived from other human herpesviruses such as HHV6 and HHV7. (See, e.g. Chee et al., Cytomegaloviruses (J. K. McDougall, ed., Springer-Verlag 1990) pp. 125-169, for a review of the protein coding content of cytomegalovirus; McGeoch et al., J. Gen. Virol. (1988) 69:1531-1574, for a discussion of the various HSV-1 encoded proteins; U.S. Pat. No. 5,171,568 for a discussion of HSV-1 and HSV-2 gB and gD proteins and the genes encoding therefor; Baer et al., Nature (1984) 310:207-211, for the identification of protein coding sequences in an EBV genome; and Davison and Scott, J. Gen. Virol. (1986) 67:1759-1816, for a review of VZV.)
Antigens from the hepatitis family of viruses, including hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), the delta hepatitis virus (HDV), hepatitis E virus (HEV) and hepatitis G virus (HGV), can also be conveniently used in the techniques described herein. By way of example, the viral genomic sequence of HCV is known, as are methods for obtaining the sequence. See, e.g., International Publication Nos. WO 89/04669; WO 90/11089; and WO 90/14436. The HCV genome encodes several viral proteins, including E1 (also known as E) and E2 (also known as E2/NSI) and an N-terminal nucleocapsid protein (termed "core") (see, Houghton et al., Hepatology (1991) 14:381-388, for a discussion of HCV proteins, including E1 and E2). Each of these proteins, as well as antigenic fragments thereof, will find use in the present composition and methods.
Similarly, the sequence for the δ-antigen from HDV is known (see, e.g., U.S. Pat. No. 5,378,814) and this antigen can also be conveniently used in the present composition and methods. Additionally, antigens derived from HBV, such as the core antigen, the surface antigen, sAg, as well as the presurface sequences, pre-S1 and pre-S2 (formerly called pre-S), as well as combinations of the above, such as sAg/pre-S1, sAg/pre-S2, sAg/pre-S1/pre-S2, and pre-S1/pre-S2, will find use herein. See, e.g., "HBV Vaccines—from the laboratory to license: a case study" in Mackett, M. and Williamson, J. D., Human Vaccines and Vaccination, pp. 159-176, for a discussion of HBV structure; and U.S. Pat. Nos. 4,722,840, 5,098,704, 5,324,513, incorporated herein by reference in their entireties; Beames et al., J. Virol. (1995) 69:6833-6838, Birnbaum et al., J. Virol. (1990) 64:3319-3330; and Zhou et al., J. Virol. (1991) 65:5457-5464.
Antigens derived from other viruses will also find use in the claimed compositions and methods, such as without limitation, proteins from members of the families Picornaviridae (e.g., polioviruses, etc.); Caliciviridae; Togaviridae (e.g., rubella virus, dengue virus, etc.); Flaviviridae; Coronaviridae; Reoviridae; Birnaviridae; Rhabodoviridae (e.g., rabies virus, etc.); Filoviridae; Paramyxoviridae (e.g., mumps virus, measles virus, respiratory syncytial virus, etc.); Orthomyxoviridae (e.g., influenza virus types A, B and C, etc.); Bunyaviridae; Arenaviridae; Retroviradae (e.g., HTLV-I; HTLV-II; HIV-1 (also known as HTLV-III, LAV, ARV, hTLR, etc.)), including but not limited to antigens from the isolates HIVIIIb, HIVSF2, HIVLAV, HIVLAI, HIVMN); HIV-1CM235, HIV-1US4; HIV-2; simian immunodeficiency virus (SIV) among others. Additionally, antigens may also be derived from human papillomavirus (HPV) and the tick-borne encephalitis viruses. See, e.g. Virology, 3rd Edition (W. K. Joklik ed. 1988); Fundamental Virology, 2nd Edition (B. N. Fields and D. M. Knipe, eds. 1991), for a description of these and other viruses.
More particularly, the gp120 envelope proteins from any of the above HIV isolates, including members of the various genetic subtypes of HIV, are known and reported (see, e.g., Myers et al., Los Alamos Database, Los Alamos National Laboratory, Los Alamos, N. Mex. (1992); Myers et al., Human Retroviruses and Aids, 1990, Los Alamos, N. Mex.: Los Alamos National Laboratory; and Modrow et al., J. Virol. (1987) 61:570-578, for a comparison of the envelope sequences of a variety of HIV isolates) and antigens derived from any of these isolates will find use in the present methods. Furthermore, the invention is equally applicable to other immunogenic proteins derived from any of the various HIV isolates, including any of the various envelope proteins such as gp160 and gp41, gag antigens such as p24gag and p55gag, as well as proteins derived from the pol region.
Influenza virus is another example of a virus for which the present invention will be particularly useful. Specifically, the envelope glycoproteins HA and NA of influenza A are of particular interest for generating an immune response. Numerous HA subtypes of influenza A have been identified (Kawaoka et al., Virology (1990) 179:759-767; Webster et al., "Antigenic variation among type A influenza viruses," p. 127-168. In: P. Palese and D. W. Kingsbury (ed.), Genetics of influenza viruses. Springer-Verlag, New York). Thus, proteins derived from any of these isolates can also be used in the compositions and methods described herein.
Antigens derived from meningitis A, meningitis B, meningitis C, and other related viruses will also find use in the compositions and methods of the present invention. For examples of meningitis B antigens see, for example, PCT 99/00695 filed Apr. 7, 1999; PCT IB98/01665 filed Oct. 9, 1998 and PCT US99/09346 filed Apr. 30, 1999.
Non-viral organisms that are controlled by T cell immune responses include: pathogenic protozoa (e.g. Pneumocystis carinii, Trypanosoma, Leishmania, Plasmodia, and Toxoplasma gondii); bacteria (e.g., Mycobacteria, and Legioniella) and fungi (e.g. Histoplasma capsulatum and Cocidioides immitus). Hence, antigens derived from these organisms are also useful in connection with the present invention.
Tumor antigens for use in the invention include, but are not limited to, melanoma tumor antigens (Kawakami et al., Proc. Natl. Acad. Sci. USA 91:3515-3519 (1994); Kawakami et al., J. Exp. Med., 180:347-352 (1994); Kawakami et al. Cancer Res. 54:3124-3126 (1994), including MART-1 (Coulie et al., J. Exp. Med. 180:35-42 (1991), gp100 (Wick et al., J. Cutan. Pathol. 4:201-207 (1988) and MAGE antigen, MAGE-1, MAGE-2 and MAGE-3 (Van der Bruggen et al., Science, 254:1643-1647 (1991)); CEA, TRP-1, P-15 and tyrosinase (Brichard et al., J. Exp. Med. 178:489 (1993)); HER-2/neu gene product (U.S. Pat. No. 4,968,603); estrogen receptor, milk fat globulin, p53 tumor suppressor protein (Levine, Ann. Rev. Biochem. 62:623 (1993)); mucin antigens (Taylor-Papdimitriou, International Pub. No. WO90/05142)); telomerases; nuclear matrix proteins; prostatic acid phosphatase; papilloma virus antigens; and antigens associated with the following cancers: melanomas, metastases, adenocarcinoma, thymoma, lymphoma, sarcoma, lung cancer, liver cancer, colon cancer, non-Hodgkins lymphoma, Hodgkins lymphoma, leukemias, uterine cancer, breast cancer, prostate cancer, ovarian cancer, cervical cancer, bladder cancer, kidney cancer, pancreatic cancer and others (e.g., Rosenberg, Ann. Rev. Med. 47:481-91 (1996).
In accordance with the invention, one or more polynucleotides are inserted ex vivo into dendritic cells, such that one or more selected antigens are presented in effective amounts on the surface of the dendritic cells. By "effective amount" is meant that presentation is sufficient to enable the dendritic cells to provoke an immune response.
Techniques for nucleic acid manipulation are well known. Reagents useful in applying such techniques, such as restriction enzymes and the like, are widely known in the art and commercially available from a number of vendors.
Large amounts of polynucleotide sequences encoding the selected antigens for expression in the dendritic cells of the invention may be obtained using known procedures for molecular cloning and replication of a vector carrying the sequences in a suitable host cell. The nucleic acid sequences for use in the present invention may also be produced in part or in total by chemical synthesis, and may be performed on commercial automated oligonucleotide synthesizers.
Polynucleotides encoding the desired antigens for presentation in the dendritic cells are preferably recombinant expression vectors in which high levels of expression may occur, and which contain appropriate regulatory sequences for transcription and translation of the inserted nucleic acid sequence. The vectors may also contain polynucleotide sequences encoding selected class I and class II MHC molecules, costimulation and other immunoregulatory molecules, ABC transporter proteins, including the TAP1 and TAP2 proteins. Thus, various combinations of polynucleotide sequences may be inserted in a suitable expression vector or vectors. The vector may contain additional elements needed for subsequent replication, such as an origin of replication. The vectors may also contain at least one positive marker that enables the selection of dendritic cells carrying the inserted nucleic acids.
Preferred recombinant expression vectors for the invention include plasmid vectors. Preferred plasmid expression vectors include pCMV (see, for example, U.S. Pat. No. 5,688,688, the entire disclosure of which is hereby incorporated by reference).
Polynucleotides encoding the desired antigen or antigens are introduced into dendritic cells using the transfection methods of the present invention discussed below.
In order to associate a polynucleotide of interest with a microparticle of interest, microparticles are simply mixed with polynucleotides, for example, in an appropriate buffer solution. The resulting formulation can be lyophilized prior to use. Generally, polynucleotides are added to the microparticles to yield microparticles with adsorbed polynucleotides having a weight-to-weight ratio of from about 0.0001:1 to 0.25:1 polynucleotides to microparticles, preferably, 0.001:1 to 0.1, more preferably 0.01 to 0.05. Polynucleotide content of the microparticles can be determined using standard techniques.
The microparticles of the present invention may have polynucleotides entrapped or encapsulated within them, as well as having polynucleotides adsorbed thereon.
The association of the microparticle with the polynucleotide is referred to alternatively herein as "polynucleotide/microparticles", "transfecting agent" and "transfection agent".
Once the dendritic cells and polynucleotide/microparticles are prepared, they are incubated in solution for a time and at a temperature sufficient for transfection to occur. According to a preferred embodiment, dendritic cells and polynucleotide/microparticles are incubated for 24 hours at 37� C. in humidified CO2 incubator.
Expression of the polynucleotide of interest after transfection into dendritic cells may be confirmed by immunoassays or biological assays. For example, expression of introduced polynucleotides into cells may be confirmed by detecting the binding to the cells of labeled antibodies specific for the antigens of interest using assays well known in the art such as FACS (Fluorescent Activated Cell Sorting) or ELISA (enzyme-linked immunoabsorbent assay) or by simply by staining (e.g., with (β-gal) and determining cell counts.
T cell activation may be detected by various known methods, including measuring changes in the proliferation of T cells, killing of target cells and secretion of certain regulatory factors, such as lymphokines, expression of mRNA of certain immunoregulatory molecules, or a combination of these.
According to an embodiment of the invention, dendritic cells transfected by polynucleotide/microparticles using any of the methods described herein are used to activate T cells in vitro. T cells or a subset of T cells can be obtained from various lymphoid tissues. Such tissues include but are not limited to spleens, lymph nodes, and peripheral blood.
The cells can be co-cultured with transfected dendritic cells as a mixed T cell population or as a purified T cell subset. For instance, it may be desired to culture purified CD8+ T cells with antigen transfected dendritic cells, as early elimination of CD4+ T cells may prevent the overgrowth of CD4+ cells in a mixed culture of both CD8+ and CD4+ T cells. T cell purification may be achieved by positive or negative selection, including but not limited to, the use of antibodies directed to CD2, CD3, CD4, CD5, and CD8. On the other hand, it may be desired to use a mixed population of CD4+ and CD8+ T cells to elicit a specific response encompassing both a cytotoxic and TH immune response.
After activation in vitro, the T cells are administered to a patient in a dose sufficient to induce or enhance an immune response to the selected antigen expressed by the dendritic cells of the invention.
T cells, as well as dendritic cells as described below, may be introduced into the subject to be treated by using one of a number of methods of administration of therapeutics known in the art. For example, the cells may be administered (with or without adjuvant) parenterally (including, for example, intravenous, intraperitoneal, intramuscular, intradermal, and subcutaneous administration). Alternatively, the cells may be administered locally by direct injection into a tumor or infected tissue. Adjuvants include any known pharmaceutically acceptable carrier. Parenteral vehicles for use as pharmaceutical carriers include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, and lactated Ringer's. Other adjuvants may be added as desired such as antimicrobials.
As an example, T cells may be administered, by intravenous infusion, at doses of about 108 to 109 cells/m2 of body surface area (see, Ridell et al., 1992, Science 257: 238-241) Infusion can be repeated at desired intervals, for example, monthly. Recipients are monitored during and after T cell infusions for any evidence of adverse effects.
According to a preferred embodiment, the T cells are obtained from the same patient from whom the dendritic cells were obtained.
According to another embodiment, the T cells are obtained from a patient and the dendritic cells, which are used to stimulate the T cells, are obtained from an HLA-matched healthy donor (e.g., a sibling), or vice versa.
According to yet another embodiment, both the T cells and the dendritic cells are obtained from an HLA-matched healthy donor. This embodiment may be particularly advantageous, for example, when the patient is a late stage cancer patient who has been treated with radiation and/or chemotherapy agents and may not be able to provide sufficient or efficient dendritic or T cells.
According to another embodiment of the invention, dendritic cells isolated from a patient are cultured, transfected in vitro and administered back to the patient to stimulate an immune response, including T cell activation. As such, the dendritic cells constitute a vaccine and/or immunotherapeutic agent. As an example, dendritic cells presenting antigen are administered, via intravenous infusion, at a dose of, for example, about 106 to 108 cells. The immune response of the patient can be monitored. Infusion can be repeated at desired intervals based upon the patient's immune response.
Below are examples of specific embodiments for carrying out the present invention. The examples are offered for illustrative purposes only, and are not intended to limit the scope of the present invention in any way.
Efforts have been made to ensure accuracy with respect to numbers used (e.g., amounts, temperatures, etc.), but some experimental error and deviation should, of course, be allowed for.
Plasmids and DNA formulations. pCMVgag plasmid encoding HIV p55 gag protein under the control of the cytomegalovirus early promoter was purified by ion-exchange chromatography using an Qiagen Endo Free Giga Kit and determined to be endotoxin free (<2.5 EU/ml). For uptake and reporter gene expression experiments, a rhodamine PNA-clamp plasmid encoding B-galactosidase was purchased from Gene Therapy Systems (San Diego, Calif.).
Cationic microparticles were prepared using a modified solvent evaporation process. The microparticles were prepared by emulsifying 10 ml of a 5% w/v polymer (RG 504 PLG (Boehringer Ingelheim)) solution in methylene chloride with 1 ml of PBS (Phosphate-Buffered Saline) at high speed using an IKA homogenizer. The primary emulsion was then added to 50 ml of distilled water containing cetyl trimethyl ammonium bromide (CTAB) (0.5% w/v). This resulted in the formation of a w/o/w emulsion, which was stirred at 6000 rpm for 12 hours at room temperature, allowing the methylene chloride to evaporate. The resulting microparticles were washed twice in distilled water by centrifugation at 10,000 g and freeze dried.
Plasmid DNA was adsorbed onto the microparticles targeting a 1% w/w load (by incubating 100 mg of cationic microparticles in a 1 mg/ml solution of DNA at 4� C. for 6 hours). The particles were separated by centrifugation, washed with TE buffer and lyophilized until use. The size distribution of the PLG-CTAB microparticles was determined using a particle size analyzer (Malvern Instruments, U.K.); formulations utilized in this study had a mean size of approximately 1 μm. Without wishing to be held to any particular theory of operation, the use of the cationic surfactant is believed to result in a net surface positive charge for the adsorption of rhodamine-labeled plasmid DNA. Actual DNA load was quantified by assaying free DNA content in the supernatant and subtracting from total input DNA. PLG-CTAB-DNA formulations utilized in this example had an actual DNA load ranging from 0.64-0.81% (w/w).
Cell culture. All cells used in this study were cultured in RPMI-1640 (BioWhittaker) supplemented with 10% heat-inactivated FBS, 2 mM glutamine, 100 U/ml penicillin, 100 n/ml streptomycin, and 0.05 mM 2-mercaptoethanol at 37� C. in a humidified 7% CO2 incubator. The murine T cell hybridoma 12.2 is an MHC class I, d-restricted line which recognizes the p7g peptide of HIV gag protein (provided by Gillis Otten, Chiron Corp.)
Bone marrow isolation. Female Balb/c mice, 6-8 weeks old, were obtained from Charles River Laboratories (Holister, Calif.). Bone marrow was flushed from the femurs and tibia, washed and frozen (−80� C.) in heat-inactivated fetal bovine serum supplemented with 10% cell-culture grade DMSO (dimethyl sulfoxide) at a density of 2�107 cells/ml.
Generation of bone-marrow-derived dendritic cells (BMDCs). Frozen cell aliquots were rapidly thawed and washed to remove DMSO. Cells were plated in 150 mm suspension culture dishes containing 20 ml supplemented RPMI (see above) with the addition of 200 units/ml murine GM-CSF (Preprotech). On day 3 of culture, cells were again supplemented with murine GM-CSF, and on day 5, one-half of the culture volume was centrifuged to replace fresh medium containing GM-CSF. BMDCs were harvested by gentle pipetting. Unless otherwise indicated, bone marrow derived dendritic cells were incubated with the gene-encoding antigen on day 6 and incubated 24 h further. BMDCs were analyzed for cell surface markers by FACS (fluorescence-activated cell sorter) and were characterized as immature by staining positive for CD11c, CD11b, H-dKd, I-Ad(low), CD80(low), and CD86(low) (PharMingen).
Cellular uptake and fluorescence microscopy. BMDCs were plated at a density of 1�106 cells in 2 ml medium in 6-well culture dishes. Rhodamine-labelled DNA in the form of naked plasmid or formulated on PLG-CTAB microparticles was added to the wells at 1 μg DNA/ml. Following overnight incubation, cells were washed and applied to Superfrost microscope slides (Fisher Scientific) by cytospin (4000 rpm�5 min). Slides were air-dried, mounted in Vectashield (Vector, Burlingame, Calif.) and visualized using a Zeiss Axiophot fluorescence microscope with rhodamine filters (Chroma, Brattleboro, Vt.). Images were documented on Kodak EliteChrome film (100 ASA) and scanned into Adobe Photoshop.
Naked plasmid DNA was readily internalized into punctate arrangements suggestive of endosomes. In contrast, the cellular distribution of rhodamine-labeled plasmid DNA formulated on PLG-CTAB-DNA microparticles suggested a more diffuse distribution of the rhodamine signal. Similar patterns of internalization have been observed with DiI-labeled microparticles as well as PLG-CTAB microparticles containing encapsulated FITC-labeled bovine serum albumin. Without wishing to be held to any particular theory, it appears as though the cationic surfactant may disrupt the endosomal compartment allowing DNA localization to the nucleus.
RNA isolation and RT-PCR. BMDCs were plated at a density of 0.5�106 cells/ml in RPMI+GM-CSF on day 6 of culture. Cells were either left untreated as negative control, or incubated in the presence of 1 μg/ml pCMV-gag DNA either alone (naked) or formulated on PLG-CTAB microspheres. Following 24 h incubation, 2�105 cells were removed, washed 2� in cold PBS (Life Technologies), then lysed per manufacturer's instructions for the mRNA Capture kit (Roche) and frozen at −80� C. Samples were thawed on ice with the addition of RNase-free DNase and RNase inhibitor (Roche). The mRNA isolation protocol was then followed for isolation of biotin-hybridized mRNA in streptavidin PCR tubes. The Promega Reverse Transcription System (Madison, Wis.) was utilized for cDNA synthesis according to manufacturer's instructions, and the reaction was run at 45� C. for 45 min, followed by heat inactivation at 99� C. for 5 min. PCR control tubes were treated as stated above but without the addition of AMV-reverse transcriptase for subsequent determination of the presence of contaminating plasmid DNA. For PCR amplification, samples were set up to amplify a 300 bp region of the HIV gag gene, or B-actin as a positive control using general PCR conditions.
Products were analyzed by agarose gel electrophoresis (
Stimulation of T cells. Bone marrow cells differentiated in the presence of GM-CSF for 6 days were classified as immature as determined by FACS analysis of cell surface phenotype CD11c+, CD11b+, H-dKd+, I-Ad(low), CD80(low), and CD86(low), and mature by day 9 (CD11c+, CD11b+, H-2Kd+, I-Ad(bright), CD80+, CD86+) (R. C. Fields, J. J. O., J. A. Fuller, E. K. Thomas, P. J. Geraghty, and J. J. Mule'. 1998. Comparative analysis of murine dendritic cells derived from spleen and bone marrow. J. Immunother. 21:323). Both immature and mature BMDCs were stimulated for 24 h with PLG-CTAB-pCMVgag DNA or naked pCMVgag DNA. Controls included untreated cells, microparticles alone or formulated with non-specific plasmid DNA (pCMV-luciferase) as well as non-specific naked DNA. T cell hybridoma 12.2 (a d-restricted T cell hybridoma specific for the p7g epitope (AMQMLKETI) of HIV p55 gag) was plated at 1�105 cells per well of a 96 well, U-bottom microtiter plates. Varying numbers of BMDCs were plated with the hybridoma in a total culture volume of 2004 Each individual experiment was performed in duplicate. After a 24 h culture period, the plates were centrifuged and the supernatants were removed and stored at −80� C. until further assay for IL-2 production. To assay for levels of IL-2 secreted into the medium, culture supernatants were thawed at room temperature and plated on pre-treated mouse IL-2 ELISA microtiter plates and analyzed per manufacturer's instructions (Endogen). Following development of colorimetric substrate, microtiter plates were read by a Molecular Devices νmax kinetic plate reader and analyzed with SoftMax software.
As shown in
In addition to being antigen specific to a d-restricted epitope of the HIV p55gag antigen, the T cell hybridoma utilized in this study was generated using the lacZ-inducible BWZ.36 fusion partner (provided by N. Shastri, U. of California Berkeley) which contains the Escherichia coli lacZ reporter gene under the control of the nuclear factor of activated T cells (NFAT) enhancer element of the IL-2 gene (Shastri, S. S. et al. 1994. LacZ inducible, antigen/MHC-specific T cell hybrids. Intl. Immunol. 6:396). To confirm the results obtained by IL-2 ELISA, we also assayed the hybridoma cells by colorimetric assay for B-galactosidase (β-galactosidase staining kit, Invitrogen). Representative cell counts from microscope fields of view indicate a significant increase of blue-stained cells over background in PLG-CTAB-pCMVgag-treated BMDCs (average counts 29 vs. 128 respectively).
The stimulation of IL-2 production by T cell recognition of antigen presented in the context of MHC class 1 molecules was found to be time-dependent. Experiments (data not included) have shown that levels of IL-2 production eventually decrease over time. However, significant levels of IL-2 are produced after 7 days (about 15% of the 24-hour IL-2 production level).
The stimulation of IL-2 production by T cell recognition of antigen presented in the context of MHC class 1 molecules was found to be dose-dependent. In
As shown in
As seen from the above, PLG-CTAB-DNA microparticles can be efficiently internalized by dendritic cells. Without wishing to be held to any particular theory, the presence of the cationic surfactants on the surface may contribute to endosome disruption and cytoplasmic or nuclear localization. Gene expression was also observed by reverse-transcriptase PCR, indicating direct transfection of BMDCs in vitro. To exploit the potent antigen uptake and presentation capabilities of dendritic cells, it was of interest to determine whether expressed antigen can be processed and presented on MHC molecules. It was seen that BMDCs incubated with PLG-CTAB microparticles formulated with pCMVgag plasmid encoding the HIV gag protein specifically stimulate antigen-specific T cell hybridoma, resulting in the production of IL-2. Moreover, it has been shown that such microparticles allow greater transfection than unmodified plasmid DNA, using the T cell hybridoma-based readout. It has also been demonstrated that pulsing of dendritic cells with PLG-CTAB-DNA is an effective mechanism for rapid internalization, target gene expression, and antigen presentation in vitro.
Although preferred embodiments of the subject invention have been described in some detail, it is understood that obvious variations can be made without departing from the spirit and the scope of the invention as defined by the appended claims.
|Cited Patent
|Filing date
|Publication date
|Oct 8, 1970
|Nov 20, 1973
|Du Pont
|Polylactide-drug mixtures
|Jun 29, 1987
|Aug 30, 1988
|Imperial Chemical Industries Plc
|Continuous release pharmaceutical compositions
|Jul 20, 1990
|Jul 28, 1992
|Debiopharm S.A.
|Method for preparing a pharmaceutical composition in the form of microparticles
|Aug 10, 1994
|Jan 21, 1997
|I.D.M. Immuno-Designed Molecules
|Polylysine conjugates
|Aug 3, 1992
|Jul 15, 1997
|Danbiosyst Uk Limited
|Preparation of microparticles
|Jan 22, 1997
|Jul 21, 1998
|Pangaea Pharmaceuticals, Inc.
|Microparticles for delivery of nucleic acid
|Jul 31, 1995
|Aug 4, 1998
|Pacific Northwest Cancer Foundation
|Isolation and/or preservation of dendritic cells for prostate cancer immunotherapy
|Jun 6, 1995
|Dec 8, 1998
|Cytel Corporation
|Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of CTL
|Jun 2, 1995
|Dec 22, 1998
|The Rockefeller University
|Method for in vitro proliferation of dendritic cell precursors and their use to produce immunogens
|Apr 30, 1996
|Dec 29, 1998
|Duke University
|Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
|Jun 5, 1995
|Sep 14, 1999
|University Of Saskatchewan
|Adjuvant formulation with enhanced immunogenic activity, and related compositions and methods
|Nov 15, 1996
|Oct 5, 1999
|St. Jude Children's Research Hospital
|Cytotoxic T lymphocyte-mediated immunotherapy
|Jul 3, 1997
|Oct 5, 1999
|Leland Stanford Junior University
|Engineered antigen presenting cells and methods for their use
|Feb 7, 1997
|May 11, 2004
|The United States Of America As Represented By The Department Of Health And Human Services
|Methods and compositions for transforming dendritic cells and activating T cells
|Jul 15, 1993
|Feb 3, 1994
|The Board Of Trustees Of Leland Stanford Junior University
|Methods for using dendritic cells to activate t cells
|Dec 2, 1993
|Jun 9, 1994
|Alkermes Controlled Therapeutics, Inc.
|Controlled release growth hormone containing microspheres
|May 9, 1996
|Nov 28, 1996
|Genentech, Inc.
|Method of administration of igf-i
|Jul 15, 1996
|Jan 30, 1997
|Danbiosyst Uk Limited
|Polymeric lamellar substrate particles for drug delivery
|Dec 20, 1996
|Jul 10, 1997
|Chiron Corporation
|Immunostimulation mediated by gene-modified dendritic cells
|Jan 29, 1998
|Aug 6, 1998
|Chiron Corporation
|Use of microparticles with adsorbed antigen to stimulate immune responses
|May 11, 1999
|Nov 18, 1999
|The Regents Of The University Of California
|Methods of forming protein-linked lipidic microparticles, and compositions thereof
|Jul 29, 1999
|Feb 10, 2000
|Chiron Corporation
|Microparticles with adsorbent surfaces, methods of making same, and uses thereof
|Andreas Lundqvist et al., "Nonviral and Viral Gene Transfer into Different Subsets of Human Dendritic Cells Yield Comparable Efficiency of Transfection," Journal of Immunology, vol. 25, No. 6, 2002, pp. 445-454.
|Awasthi S. Cox. Abstract of "Transfection of Murine Dendritic Cell Line (JAWS II) by a Nonviral Transfection Reagent," Biotechniques, vol. 35, No. 3, 2003, pp. 600-602, 604.
|Banchereau, J.B. et al., "Dendritic Cells and the Control of Immunity," Nature, 1998, 392:245.
|Ciftci K. et al. "DNA-PLGA Microparticles: A Promising Delivery System for Cancer Gene Therapy," AAPS Annual Meeting Abstracts Oneline 1( ):1999.
|D.T. O'Hagan et al., "Long-Term Antibody Responds in Mice Following Subcutaneous Immunization with Ovalbumin Entrapped in Biodegradable Microparticles," Vaccine, vol. 11, No. 9, 1993, pp. 965-969.
|Denis-Mize et al., "Cationic Microparticles as a Delivery System for DNA Vaccines" Abstracts of the General Meeting of the American Society for Microbiology Session No. 214/D, Abstract D-224, May 24, 2000.
|Denis-Mize, KS et al., "Plasmid DNA adsorbed onto cationic microparticles mediates target gene expression and antigen presentation by dendritic cells," Gene Therapy (2000) 7, 2105-2112.
|E. Fattal et al., "Biodegradable polyalkylcyanoacrylate nanoparticles for the delivery of oligonucleotides" Journal of Controlled Release, 53 (1998) 137-143.
|Elke Walter et al., "Microencapsulation of DNA Using Poly (DL-Lactide-CO-Glycolide): Stability Issues and Release Characteristics, "Journal of Controlled Release, vol. 61, 1999, pp. 361-374.
|Fattal et al. (1998) J. Controlled. Rel., vol. 53, 137-143.
|Hedley et al., "Microspheres Containing Plasmid-Encoded Antigens Elicit Cytotoxic T-Cell Response" Nature Medicine 4(3):365-368, Mar. 1998.
|Karhumaki et al., "An Improved Enrichment method for functionally competent, highly purified peripheral blood dendritic cells and its application to HIV-infected blood samples" Clin Exp Immunol 1993; 91:482-488.
|L. Zhong et al., Abstract of "Recombinant Adenovirus Is an Efficient and Non-Perturbing Genetic Vector for Human Dendritic Cells", Eur. J. Immunol., vol. 29, No. 3, 1999, pp. 964-972.
|Manickan et al. (1997) J. Leuk. Biol., vol. 61, 125-132.
|P. Lenz et al., Abstract of "Necleoporation of Dendritic Cells: Efficient Gene Transfer by Electroporation into Human onocyte-Derived Dendritic Cells," FEBS Lett, vol. 538, No. 1-3, 2003, pp. 149-154.
|Scheicher et al., "Uptake of Microparticle-Adsorbed Protein Antigen by Bond Marrow-Derived Dendritic Cells Results in Up-Regulation of Interleukin-1alpha and Interleukin-12 p40/p35 and Triggers Prolonged, Efficient Antigen Prsentation" Eur. J. Immunol. 25:1566-1572, 1995.
|Scheicher et al., "Uptake of Microparticle-Adsorbed Protein Antigen by Bond Marrow-Derived Dendritic Cells Results in Up-Regulation of Interleukin-1α and Interleukin-12 p40/p35 and Triggers Prolonged, Efficient Antigen Prsentation" Eur. J. Immunol. 25:1566-1572, 1995.
|Shibagaki N. Udey, Abstract of "Dendritic Cells Transduced with Protein Antigens Induced Cytotoxic Lymphocytes and Elicit Antitumor Immunity," Journal of Immunology, vol. 168, No. 5, 2002, pp. 2393-2401.
|Shuichi Ando et al., "PLGA Microspheres Containign Plasmid DNA: Preservation of Supercoiled DNA via Cytotoxic Lymphocytes and Elicit Antitumor Immunity," Journal of Immunology, vol. 168, No. 5, 2002, pp. 2393-2401.
|Singh et al., "Cationic Microparticles: A Potent Deliver System for DNA Vaccines" Proc. Natl. Acad. Sci. 97(2):811-816, Jan. 18, 2000.
|Singh M et al. "Cationic microparticles: A potent delivery system for DNA vaccines," Proc Natl Acad Sci USA, Jan. 18, 2000, vol. 97, No. 2, pp. 811-816.
|Spahn et al. (1996) Proc. Am. Assoc. Canc. Res., vol. 37, 486-487.
|Steinman, R.M., "The Dentritic Cells System and Its Role in Immunogenicity", Ann. Rev. Immunol. 1991, 9:271.
|Takashima A. Morita, Abstract of "Dendritic Cells in Genetic Immunization," Journal of Leukocyte Biology, vol. 66, No. 2, 1999, pp. 350-356.
|Tuting et al. (1998) J. Immunol., vol. 160,1139-1147.
|U.S. Appl. No. 09/015,652.
|Yang et al. (1999) Int. J. Cancer, vol. 83, 532-540.
|Citing Patent
|Filing date
|Publication date
|Mar 13, 2013
|Sep 19, 2013
|Macrocure, Ltd.
|Activated immunostimulatory cell composition and uses thereof
|Mar 13, 2013
|Sep 19, 2013
|Macrocure, Ltd.
|Activated immunostimulatory cell composition for therapy of infection
|U.S. Classification
|424/93.21, 435/455, 424/93.71, 435/347
|International Classification
|Cooperative Classification
|European Classification
|Jan 11, 2011
Owner name: NOVARTIS VACCINES AND DIAGNOSTICS, INC., CALIFORNI
Free format text: CHANGE OF NAME;ASSIGNOR:CHIRON CORPORATION;REEL/FRAME:025621/0723
Effective date: 20060419
Owner name: CHIRON CORPORATION, CALIFORNIA
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:DONNELLY, JOHN J.;DENIS-MIZE, KIMBERLY S.;OTT, GARY S.;SIGNING DATES FROM 20010116 TO 20010117;REEL/FRAME:025621/0664
|Jul 8, 2015
|Fee payment
Year of fee payment: 4


text:
North Carolina Crafts - Take Home Handmade Treasure
Posted November 9, 2006
Updated January 4, 2007
The object was a woven double bowknot coverlet, given as a humble gift of friendship to Presbyterian missionary Frances Goodrich. So taken was she by the coverlet's meticulous handiwork, Ms. Goodrich was inspired to save the fast-disappearing mountain traditions that had gone into producing it. The result was the formation of Allanstand Craft Shop, opened in 1895 and presently America's oldest continuously operated craft shop.
Today, two North Carolina organizations in particular are dedicated to carrying on the time-honored handicrafts traditions Ms. Goodrich made it her life's work to preserve – each of which is worthy of a day trip (or longer). Both organizations provide oases of craftsmanship and beauty in an increasingly pre-fab, homogenized, mass-produced world.
The Southern Highland Craft Guild
Housed in the Blue Ridge Parkway's Folk Art Center (five miles outside of Asheville), the Guild has promoted crafts made by accomplished Mountain artists for seven decades. The Center is now home to Allanstand, which occupies 3,000 of its 30,500 square feet, as well as three other craft shops. Walk into the building, and you're surrounded by the finest work of the Guild's more than 700 member artists: ornate quilts and baskets, magnificent pottery, jewelry, woodwork, lovingly crafted paper, glass, metalwork and more.
Selections from the Guild's Permanent Collection, a 3,500-piece assemblage of craft objects dating back to the turn of the 20th century, can be seen at the Center during special exhibitions. From April through December, you can also observe craftspeople at work in daily demonstrations, as well as take in a host of other special events.
To find out more, go to www.southernhighlandguild.org/folkart.html or call 828-298-7928.
Penland School of Crafts
Much like the Southern Craft Guild, the impetus for Penland's founding was provided by a visionary and determined woman: Lucy Morgan. Similar to Ms. Goodrich, "Miss Lucy" had observed firsthand the impoverished conditions of what was then a woefully isolated area. She noticed in particular how the machine-made goods of the Industrial Revolution were beginning to threaten the age-old mountain tradition of handweaving.
So, in 1923, with just three looms, Miss Lucy established the Penland Weavers to help revive the vanishing craft and supplement the locals' subsistence-level incomes. The looms hummed with the activity of skilled hands, and it wasn't long before additional instruction was offered in pottery, spinning and dyeing, and other traditional arts.
Word of Miss Lucy's success quickly spread, which led to the establishment of the Penland School of Crafts in 1929. Lucy Morgan's inspiring mission is still being carried on at the School today, although with a somewhat more contemporary emphasis. In fact, the School's educational program has for years attracted world-renowned instructors, along with serious craft students who range from novices to professionals.
At the Penland Gallery, you can see and buy work by resident artists and students, as well as Penland's instructors. The Gallery also presents special exhibitions, twice-weekly tours of the campus and occasional craft demonstrations. But be forewarned, visiting here may seduce you into becoming a student yourself.
Located near the charming town of Spruce Pine, Penland School offers one, two and eight-week classes in books and paper, clay, drawing, glass, iron metals, photography, printmaking, textiles and wood.


text: CHICAGO, Dec. 6, 2011 /PRNewswire/ -- The Female Health Company (NASDAQ: FHCO) today announced that on World AIDS Day, December 1, 2011, the British Government pledged five million pounds (approximately $7.8 M) for the purchase of female condoms to enhance reproductive health needs of women. The fund, which will be channeled through the Department of International Development to the United Nations Population Fund (UNFPA) is additional to the 35 million pounds generally provided for contraceptive supplies to save the lives of thousands of women who urgently need contraception supplies. The British International Development Minister Stephen O'Brian made the announcement at a plenary session on "Family Planning and HIV: Strange Bedfellows No More" at the on-going second international conference on Family Planning in Dakar. Mr. O'Brian said AIDS is a major cause of maternal deaths in high prevalence countries and there is the need to put in measures to address and halt the spread of the virus. The British Minister said there is the urgent need for a comprehensive approach that will ensure the integration of quality sexual reproductive health, including prevention of the HIV/AIDS virus, and family planning needs. He explained that millions of unintended pregnancies occur every year because 215 million women who want desperately to delay or avoid their pregnancies are not able to do so. He said the provision of the fund will ensure that two million unintended pregnancies are prevented. O.B. Parrish, Chairman and C.E.O. of The Female Health Company, noted that "the Company lauds the British Government for its concern and support of women's reproductive health concerns world-wide". About The Female Health Company The Female Health Company, based in Chicago, Illinois, manufactures and markets the FC2 Female Condom® (FC2), which is available in the U.S. and in about 120 other countries globally. The Company owns certain worldwide rights to the FC2 Female Condom®, including patents that have been issued in the U.S., the European Union, Canada, Australia, South Africa, Japan, The People's Republic of China, Spain, Mexico, Greece, Turkey and the African Regional Intellectual Property Organization (ARIPO), which includes Botswana, The Gambia, Ghana, Kenya, Lesotho, Malawi, Mozambique, Namibia, Sierra Leone, Somalia, Sudan, Swaziland, Uganda, United Republic of Tanzania, Zambia and Zimbabwe. FC2 patent applications are pending in various countries. The FC2 Female Condom® is the only available FDA-approved product controlled by a woman that offers dual protection against sexually transmitted diseases, including HIV/AIDS, and unintended pregnancy. The World Health Organization (WHO) has cleared FC2 for purchase by U.N. agencies.


text:
The Topline: Pentagon officials said Thursday they are standing behind President Obama's 2015 defense budget blueprint, despite the House Armed Services Committee batting down many of those proposals.
"We stand firmly behind the president's budget as submitted," said Pentagon spokesman Army Col. Steve Warren. He added that it was long-standing policy not to comment on legislation that's being drafted.
The Armed Services committee unanimously passed its 2015 defense authorization bill just after midnight, early on Thursday, which if passed into law, would prevent many cuts the Pentagon says are needed.
The full House will vote on the bill in two weeks. It would then have to be reconciled with a Senate version of the legislation.
Several members of the Senate Armed Services Committee have indicated they would also reject plans to retire the A-10 and transfer the National Guard's attack helicopters to the active duty Army.
Military chiefs have warned that if they are not allowed to make those cuts, they will have to redraft their 2015 defense budget requests. But on Thursday, Pentagon officials said it was still too early to predict the next step.
Shinseki to testify: It's been a rough week for Veterans Affairs Secretary Eric Shinseki. After allegations that veterans at a second VA clinic were being placed on secret waiting lists to obscure long wait times, several lawmakers and veterans groups this week called for his resignation.
On Thursday, the House Veterans Affairs Committee announced it was subpoenaing Shinseki to testify before the committee on the allegations, and separately the Senate Veterans Affairs Committee announced a hearing next Thursday where he would testify.
The Senate committee's chairman, Sen. Bernie SandersBernie SandersFunding confusion complicates Meals on Wheels budget fight The Hill's 12:30 Report Five takeaways from the Montana special election MORE (I-Vt.), said the hearing next Thursday will take a broader look at the overall VA healthcare system.
Sanders has not called for Shinseki's resignation, saying he would wait until the VA inspector general investigated the claims that veterans died while waiting for treatment.
"I expect the [VA] inspector general will conduct the investigation thoroughly and provide this committee with an objective analysis of these allegations," he said.
Sanders noted that "some 200,000 veterans get care every single day," and that "independent studies show that VA provides, in general, excellent care to our veterans."
However, he added, "in a system as large and bureaucratic as the VA, it is imperative that we uncover the problems that exist in the system and address them boldly."
Senators applaud A-10 save: A group of GOP senators lauded the House Armed Services Committee for staving off the mothballing of the A-10 Thunderbolt II aircraft fleet for at least another year.
The panel, in its marathon mark up of the 2015 National Defense Authorization Act, easily adopted an amendment sponsored by Rep. Ron BarberRon BarberGiffords to lawmakers avoiding town halls: 'Have some courage' Ten House seats Dems hope Trump will tilt House conducts moment of silence for Tucson shooting anniversary MORE (D-Ariz.) that delays the retirement of the aircraft, dubbed by troops as the "Warthog," for one year and requires the Pentagon to study whether other aircraft can provide adequate close air support.
"We applaud the committee members for honoring our commitment to provide our troops the best possible close air support so they can accomplish their missions and return home safely," Sens. Kelly AyotteKelly AyotteWeek ahead: Comey firing dominates Washington GOP senators pitch Merrick Garland for FBI director Kelly Ayotte among candidates to be FBI director: report MORE (R-N.H.) John McCainJohn McCainMcCain: Putin a greater threat than ISIS Trump's defense spending boom that wasn't Defense hawks gird for budget brawl MORE (R-Ariz.), Lindsey GrahamLindsey GrahamGraham: Calling climate change a 'hoax' bad for GOP Graham: Comey should be held accountable for acting on bad intel Trump got harsher GOP reception than Bush on budget MORE (R-S.C.) and Saxby ChamblissSaxby ChamblissGOP hopefuls crowd Georgia special race Democrats go for broke in race for Tom Price's seat Spicer: Trump will 'help the team' if needed in Georgia special election MORE (R-Ga.) said in a joint statement.
The Air Force wants to retire the 283-plane fleet to save $3.5 billion over the next five years.
The Republican senators vowed to defend the Warthog fleet when the Senate Armed Services Committee takes up its version of the defense authorization bill later this month.
Afghan visa revamp: A coalition of lawmakers debuted a proposal to allow more Afghan civilians who have served as interpreters and guides to get visas to the United States.
The legislation, endorsed by Sens. Jeanne Shaheen Jeanne ShaheenSenate panel approves Scott Brown as NZ ambassador Senators pan WH proposal to cut airport security programs, hike ticket fees Dem senator: 'One of our closest allies' expressed concern about intelligence sharing MORE (D-.N.H.) and John McCain (R-Ariz.) and Reps. Earl BlumenauerEarl BlumenauerA unifying cause in Congress: animal protection House Dem seeks to create commission on 'presidential capacity' Medical marijuana supporters hopeful about government funding bill MORE (D-Ore.) and Adam Kinzinger (R-Ill.) would prolong the 2009 Special Immigrant Visa (SIV) effort for another fiscal year.
The proposed measure would also expand the eligibility of the program to include Afghans who helped the International Security Assistance Force, media outlets and non-profits organizations, as well as their families.
It would also approve an additional 3,000 visas and allow any unused slots from fiscal 2014 to be carried over.
"We have a responsibility to fulfill the obligation to the thousands of civilians who risked their lives to help our country during a time of war," Shaheen said at a joint press conference on the measure.
In Case You Missed It:
-FLOTUS will meet veterans with Landrieu
-Ranking Democrat seeks legal status for illegal immigrants in military
-Reid sets up vote on O-Care tweak for veterans
-No plans for Obama-Putin meeting in France
-Casey to Obama: We must do more in Syria
Please send tips and comments to Kristina Wong, email@example.com and Martin Matishak, firstname.lastname@example.com.
Follow us on Twitter: @thehill @kristina_wong @martinmatishak


text:
LOS ANGELES -- By his own admission, Tom Glavine wasn't very good in his quest to become baseball's first nine-game winner.
Thanks to the New York Mets' offense, he was good enough.
Glavine pitched 5 1/3 shaky innings in his shortest and least effective outing of the season and Carlos Beltran and David Wright each had three hits for the Mets in a 9-7 victory over the Los Angeles Dodgers on Wednesday night.
Rookie Lastings Milledge tripled and homered, drove in three runs and made a key defensive play for the Mets, who won two of three in the series and are 13-5 with two ties in their 20 series this season.
Glavine (9-2) allowed seven hits and six runs before being relieved by Chad Bradford with one on and one out in the sixth and the Mets leading 7-6.
"It wasn't pretty, but I'll take it," the 40-year-old left-hander said. "You've got to win games like that once in a while. Tonight was one of those games I didn't deserve to win, but I did. I've certainly had my share of games I didn't deserve to lose, but I did. They all even out -- at least you hope they do."
Glavine walked three, struck out one and gave up three homers -- two by Rafael Furcal. But he earned his 284th career victory, moving him into a tie for 26th on baseball's all-time list.
Glavine, lifted after 93 pitches, gave up a total of 23 earned runs in his first 12 starts. He started on three days' rest for the 25th time in his career and the first since Aug. 19, 2003. He was 7-6 with a 3.29 ERA in such situations.
"I felt too good," he said. "This is what I would have anticipated I would have felt last time, and I had seven days off."
The Mets remained 3½ games ahead of second-place Philadelphia in the NL East, while the Dodgers trail NL West-leading Arizona by 1½ games.
Milledge hit a two-out, two-run homer off Jae Seo in the seventh to give the Mets a 9-6 lead. Then, Nomar Garciaparra hit a liner down the left field line to open the eighth against Duaner Sanchez, but was thrown out by Milledge trying to stretch the hit into a double.
Pinch-hitter Andre Ethier hit a two-out, RBI double later in the inning before Sanchez struck out pinch-hitter Olmedo Saenz to end the inning.
Billy Wagner, the Mets' fifth pitcher, worked a 1-2-3 ninth for his 12th save.
"You don't know how a young guy is going to do," Mets manager Willie Randolph said of the 21-year-old Milledge, who was playing in his eighth big league game. "It's nice to see the kid help us out. Big, tremendous home run; a great throw. He's making a nice case for himself."
Milledge was brought up from the minors last week when Xavier Nady underwent an appendectomy.
The Mets took a 4-0 lead off Odalis Perez (4-2) in the first inning on five straight two-out hits. Beltran and Wright singled and, after a double steal, scored on a single by Julio Franco. Jose Valentin followed with an RBI double and scored on Milledge's first career triple.
Furcal hit Glavine's third pitch over the left field fence in the bottom of the inning for the 13th leadoff homer of his career.
Beltran hit an RBI single in the second, but the Dodgers tied the game in their half on an RBI single by rookie Russell Martin and a two-out, three-run homer by Furcal, his fourth of the season.
The Mets scored twice and chased Perez in the fourth on consecutive two-out singles by Chris Woodward, Paul Lo Duca, Beltran and Wright. Jose Cruz Jr. hit Glavine's second pitch in the bottom of the inning for his fourth homer to draw the Dodgers within one.
Perez, making first start since May 2, allowed seven runs and 11 hits in 3 2/3 innings. Nine of the hits came with two outs.
"I don't think there is any mechanical problem. No way," Perez said. "I felt good tonight and I threw the ball the way I was supposed to throw it. They scored seven runs off me, but at the same time, you saw how many broken-bat bloopers they hit off me."
Dodgers manager Grady Little said Perez wouldn't be removed from the rotation again - at least for now.
"The first three hits of the game all came on shattered bats, and there's nothing in the world you can do about that," Little said. "After that, they hit a couple of balls good."
- Dodgers OF J.D. Drew didn't start because of tightness in his right hamstring. He walked as a pinch hitter in the eighth and scored on Ethier's double.
- The Mets played without SS Jose Reyes (sore right wrist) and LF Cliff Floyd (sprained left ankle). Both are day to day.
- Dodgers rookie Willy Aybar singled in the seventh to extend his hitting streak to 13 games. Garciaparra had two hits to extend his hitting streak to 11 games.
- Franco made his third start of the season, giving 1B Carlos Delgado a rest, and went 1-for-5. The 47-year-old Franco is the oldest player in the majors.